AI Engines For more Details: Perplexity Kagi Labs You
Antioxidant Activity: Sulforaphane exhibits strong antioxidant properties, meaning it can neutralize harmful free radicals in the body. Free radicals are molecules that can cause oxidative damage to cells and contribute to aging and various diseases. By scavenging free radicals, sulforaphane helps to protect cells from oxidative stress and reduce the risk of oxidative damage to tissues throughout the body.
Anti-inflammatory Effects: Sulforaphane has been shown to possess anti-inflammatory properties, meaning it can reduce inflammation in the body. Chronic inflammation is associated with the development and progression of various diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. By inhibiting inflammatory pathways and reducing the production of inflammatory molecules, sulforaphane may help to alleviate symptoms and slow the progression of these diseases.
Cancer Prevention: Sulforaphane has been extensively studied for its potential anti-cancer properties. It helps to inhibit the growth of cancer cells, induce apoptosis (programmed cell death), and prevent the spread of cancerous tumors. Sulforaphane may also help to reduce the risk of cancer by modulating signaling pathways involved in cell growth, proliferation, and survival. It has been studied in various types of cancer, including breast, prostate, lung, colon, and skin cancer.
Detoxification and Liver Health: Sulforaphane may support detoxification processes in the body, particularly in the liver. It helps to activate phase II detoxification enzymes, which are responsible for the metabolism and elimination of toxins and carcinogens. Sulforaphane may also help to protect the liver from damage caused by environmental toxins, alcohol, and other harmful substances.
Neuroprotective Effects: Some research suggests that sulforaphane may have beneficial effects on brain health and cognitive function. It helps to protect neurons from oxidative damage, reduce inflammation in the brain, and modulate signaling pathways involved in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Sulforaphane may also help to improve memory and cognitive function.
Cardiovascular Health: Sulforaphane has been studied for its potential benefits in promoting cardiovascular health. It helps to improve endothelial function, reduce inflammation in blood vessels, and lower cholesterol levels. Sulforaphane may also help to prevent the formation of blood clots and reduce the risk of cardiovascular diseases such as atherosclerosis, hypertension, and heart disease.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 0.8 | 0.8 | |
| ADHD | 1 | 0.5 | 1 |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.2 | 5 |
| Allergies | 1.8 | 1.1 | 0.64 |
| Allergy to milk products | 0.8 | 1.2 | -0.5 |
| Alzheimer's disease | 2.6 | 1.3 | 1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.5 | 2.8 |
| Ankylosing spondylitis | 2.8 | 1.7 | 0.65 |
| Anorexia Nervosa | 0.8 | 0.2 | 3 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 1.5 | 1 | 0.5 |
| Atherosclerosis | 0.2 | 0.4 | -1 |
| Atrial fibrillation | 1.3 | 2 | -0.54 |
| Autism | 3.7 | 3.2 | 0.16 |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Bipolar Disorder | 1.1 | 0.8 | 0.38 |
| Brain Trauma | 0.7 | 1.8 | -1.57 |
| Carcinoma | 0.8 | 0.5 | 0.6 |
| Celiac Disease | 0.7 | 1.3 | -0.86 |
| Cerebral Palsy | 0.2 | 0.3 | -0.5 |
| Chronic Fatigue Syndrome | 2.4 | 0.6 | 3 |
| Chronic Kidney Disease | 1.3 | 1.3 | |
| Chronic Lyme | 0.5 | 0.2 | 1.5 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.2 | |
| Chronic Urticaria (Hives) | 0.4 | 0.4 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.8 | 0.8 | |
| Colorectal Cancer | 3.4 | 0.5 | 5.8 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 0.2 | 0.2 | |
| COVID-19 | 3 | 1.8 | 0.67 |
| Crohn's Disease | 2.4 | 1.2 | 1 |
| cystic fibrosis | 0.3 | 0.2 | 0.5 |
| deep vein thrombosis | 0.7 | 0.7 | |
| Depression | 4.3 | 3.9 | 0.1 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 2.4 | 0.3 | 7 |
| Endometriosis | 1.2 | 0.7 | 0.71 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 1.7 | 0.5 | 2.4 |
| Fibromyalgia | 0.2 | 0.2 | 0 |
| Functional constipation / chronic idiopathic constipation | 2.5 | 0.8 | 2.13 |
| gallstone disease (gsd) | 0.5 | 0.2 | 1.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | 0 |
| Generalized anxiety disorder | 0.3 | 0.7 | -1.33 |
| giant cell arteritis | 0.5 | 0.3 | 0.67 |
| Glioblastoma | 0.2 | -0.2 | |
| Gout | 1.4 | 1.4 | |
| Graves' disease | 1.8 | 1 | 0.8 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.3 | 0.3 | 0 |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 1 | 0.3 | 2.33 |
| Hyperlipidemia (High Blood Fats) | 0.6 | -0.6 | |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 2.1 | 1.3 | 0.62 |
| Hypothyroidism | 0.6 | 0.6 | |
| Hypoxia | 0.2 | 0.2 | 0 |
| IgA nephropathy (IgAN) | 0.5 | 0.3 | 0.67 |
| Inflammatory Bowel Disease | 1 | 0.5 | 1 |
| Insomnia | 0.7 | 0.8 | -0.14 |
| Intelligence | 0.8 | -0.8 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 2.3 | 1.2 | 0.92 |
| Liver Cirrhosis | 2.3 | 1 | 1.3 |
| Long COVID | 3.9 | 4 | -0.03 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0.3 | 0.3 | 0 |
| ME/CFS with IBS | 0.2 | 0.2 | 0 |
| ME/CFS without IBS | 0.5 | -0.5 | |
| Metabolic Syndrome | 4 | 2.2 | 0.82 |
| Mood Disorders | 5 | 5 | 0 |
| Multiple Sclerosis | 0.9 | 1.3 | -0.44 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| Neuropathy (all types) | 0.3 | 0.4 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 0.5 | 1 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 1.8 | -0.5 |
| Obesity | 2.6 | 2.2 | 0.18 |
| obsessive-compulsive disorder | 1.2 | 0.8 | 0.5 |
| Osteoarthritis | 0.3 | 0.3 | |
| Osteoporosis | 1.3 | 1.3 | 0 |
| Parkinson's Disease | 2.4 | 1.3 | 0.85 |
| Polycystic ovary syndrome | 2 | 1 | 1 |
| Postural orthostatic tachycardia syndrome | 0.5 | 0.5 | |
| Premenstrual dysphoric disorder | 0.6 | 0.3 | 1 |
| primary biliary cholangitis | 0.2 | 0.2 | |
| Psoriasis | 0.2 | 0.9 | -3.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.5 | 2.6 | 0.35 |
| Rosacea | 0.3 | 0.2 | 0.5 |
| Schizophrenia | 2.1 | 1.2 | 0.75 |
| scoliosis | 0.2 | -0.2 | |
| sensorineural hearing loss | 0.5 | 0.5 | |
| Sjögren syndrome | 0.7 | 0.5 | 0.4 |
| Sleep Apnea | 0.7 | 0.8 | -0.14 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1.3 | 0.2 | 5.5 |
| Systemic Lupus Erythematosus | 2.6 | 1.9 | 0.37 |
| Tic Disorder | 0.2 | 0.7 | -2.5 |
| Tourette syndrome | 0.2 | 0.4 | -1 |
| Type 1 Diabetes | 1.3 | 0.7 | 0.86 |
| Type 2 Diabetes | 3.1 | 2.2 | 0.41 |
| Ulcerative colitis | 2.6 | 2.6 | 0 |
| Unhealthy Ageing | 0.7 | 0.2 | 2.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.